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232Randomized Control of Sympathetic Drive With
Continuous Intravenous Esmolol in Patients With
Acute ST-Segment Elevation Myocardial Infarction
The BEtA-Blocker Therapy in Acute Myocardial
Infarction (BEAT-AMI) TrialABSTRACTOBJECTIVES This study sought to evaluate the role of esmolol-induced tight sympathetic control in patients with
ST-segment elevation myocardial infarction (STEMI).
BACKGROUND Elevated sympathetic drive has a detrimental effect on patients with acute STEMI. The effect of
beta-blocker-induced heart rate mediated sympathetic control on myocardial damage is unknown.
METHODS The authors conducted a prospective, randomized, single-blind trial involving patients with STEMI and
successful percutaneous intervention (Killip class I and II). Patients were randomly allocated to heart rate control with
intravenous esmolol for 24 h or placebo. The primary outcome was the maximum change in troponin T release as a
prognostic surrogate marker for myocardial damage. A total of 101 patients were enrolled in the study.
RESULTS There was a signiﬁcant difference between patients allocated to placebo and those who received sympathetic
control with esmolol in terms of maximum change in troponin T release: the median serum troponin T concentration
increased from 0.2 ng/ml (interquartile range [IQR] 0.1 to 0.7 ng/ml) to 1.3 ng/ml (IQR: 0.6 to 4.7 ng/ml) in the esmolol
group and from 0.3 ng/ml (IQR: 0.1 to 1.2 ng/ml) to 3.2 ng/ml (IQR: 1.5 to 5.3 ng/ml) in the placebo group (p¼ 0.010). The
levels of peak creatine kinase (CK), CK subunit MB (CK-MB), and n-terminal brain natriuretic peptide (NT-proBNP) were
lower in the esmolol group compared with placebo (CK 619 U/l [IQR: 250–1,701 U/l] vs. 1,308 U/l [IQR: 610 to 2,324 U/l];
p¼ 0.013; CKMB: 73.5 U/l [IQR: 30 to 192 U/l] vs. 158.5 U/l [IQR: 74 to 281 U/l]; p¼0.005; NT-proBNP: 1,048 pg/ml (IQR:
623 to 2,062 pg/ml] vs. 1,497 pg/ml [IQR: 739 to 3,318 pg/ml]; p¼ 0.059). Cardiogenic shock occurred in three patients in
the placebo group and in none in the esmolol group.
CONCLUSIONS Esmolol treatment statistically signiﬁcantly decreased troponin T, CK, CK-MB and NT-proBNP release as
surrogate markers for myocardial injury in patients with STEMI. (Heart Rate Control After Acute Myocardial Infarction;
DRKS00000766) (J Am Coll Cardiol Intv 2016;9:231–40) © 2016 by the American College of Cardiology Foundation.A dmission heart rate in patients with acutemyocardial infarction (AMI) is an indepen-dent prognostic indicator for cardiovascular
morbidity and mortality (1,2). Enhanced sympathetic
drive triggers additional myocardial cell damage in
the very acute phase of AMI (3–5). Elevated heart
rate is the obvious indicator for sympathetic activity.SEE PAGE 241Beta-blockade might be helpful to limit unfavor-
able inﬂuences of sympathetic activity on cardiac
regeneration during AMI (6,7). The use of beta-
blockade during the acute phase of AMI is a matter
of discussion. Administration of oral beta-blocker in
patients with AMI is recommended and established(8,9). However, routine use of intravenous beta-
blockade is not recommended. This reservation is
on the basis of historical trials, which demonstrated
increasing risk for cardiogenic shock in patients with
severe myocardial infarction, reﬂected by higher
Killip classes (10). In daily clinical settings intrave-
nous beta-blocker is usually not given systematically.
We hypothesized that beta-blockade in acute ST-
segment elevation myocardial infarction (STEMI)
might be helpful to suppress the sympathetic drive.
We thought that heart rate might be an applicable tool
to assess the individual sympathetic activity (11) and
determine dosage of intravenous beta-blockade.
The BEAT-AMI (BEtA-Blocker Therapy in Acute
Myocardial Infarction) study to our knowledge is the
ﬁrst in which continuous intravenous beta-blocker is
AB BR E V I A T I O N S
AND ACRONYM S
AMI = acute myocardial
infarction
APPROACH = Alberta
Provincial Project for Outcome
Assessment in Coronary Heart
Disease score
AUC = area under the curve
BARI = Bypass Angioplasty
Revascularization Investigation
Myocardial Jeopardy Index
CK = creatine kinase
CK-MB = creatine kinase
subunit MB
HR = heart rate
IQR = interquartile range
NT-proBNP = n-terminal brain
natriuretic peptide
PCI = percutaneous coronary
intervention
STEMI = ST-segment elevation
myocardial infarction
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233administrated in the very acute phase of STEMI with a
predeﬁned goal to effectively control sympathetic
activity reﬂected by a target heart rate of 60
beats/min and mean arterial blood pressure of more
than 65 mm Hg (12).
METHODS
STUDY OVERSIGHT. The BEAT-AMI investigators con-
ceived, designed, and conducted the beta-blocker for
tight heart rate control in patients with acute STEMI
(BEAT-AMI) trial. The study protocol was approved by
the ethics committee of the University of Cologne (Uni-
Koeln-1392; 11-080) and the Federal Institute for Drugs
andMedical Devices (61-3910-4037242). The Center for
Clinical Trials Cologne served as the data and study-
coordinating institute (CMMC Cologne). All patients
provided written informed consent.
STUDY DESIGN. BEAT-AMI was a single center, 1:1
randomized, single-blind, placebo-controlled trial of
esmolol in patients with acute STEMI and successful
percutaneous coronary intervention (PCI) in a pre-
deﬁned timeline of <6 h between symptom onset and
PCI. Patients were required to have a Killip class I or II
STEMI, a baseline heart rate >60 beats/min and a
mean arterial blood pressure >65 mm Hg (Online
Study Protocol).
STUDY DRUG, RANDOMIZATION, AND BLINDING.
Study treatment in BEAT-AMI was started immedi-
ately after transfer from the catheter laboratory to the
intensive care unit within 60 min between PCI and
onset of treatment. Active therapy consisted of
weight-adapted continuous plus additional bolus
esmolol infusion, targeting a heart rate of 60
beats/min. Patients were blinded to the treatment.
Placebo-treated subjects received continuous 0.9%
sodium-chloride infusion. Follow-up procedures
were analyzed by a blinded investigator (E.C.).
Randomization with an allocation ratio of 1:1 was on
the basis of permuted blocks of varying length and
was implemented using sequentially numbered,
opaque, and sealed envelopes.
STANDARD CARE PROCEDURES. All patients during
PCI received guideline-directed standard medication,
including aspirin and clopidogrel, prasugrel, or tica-
grelor. There were no limitations on additional indi-
cated drug therapy. All patients received for
secondary prevention oral beta-blocker, aspirin,
P2Y12-receptor antagonist, and statin.
STUDY ENDPOINTS. For the primary endpoint, the
maximum change in troponin T from baseline to 48 h
(peak troponin T minus baseline troponin T) waschosen as a surrogate marker for cardiac
damage and a suitable prognostic indicator
(13–16). To compute the maximum troponin
values, we used all valid measurements
within 48 h after the beginning of the study
intervention. The secondary endpoints in-
cluded concentrations of creatine kinase (CK),
CK isoenzyme MB (CK-MB), and n-terminal
brain natriuretic peptide (NT-proBNP) at 48 h,
the echocardiographic ejection fraction at
48 h, 6 weeks, and 6 months, the 6-min
walking test at 6 weeks and 6 months, and
assessment of quality of life (EQ5D, data not
shown) at 48 h, 6 weeks, and 6 months.
The safety endpoints were incidence of
cardiogenic shock, symptomatic bradycardia
or hypotension, re-angina pectoris, repeated
angiography and target vessel revasculariza-
tion, rehospitalization, cerebral insult, and
mortality.
STATISTICAL ANALYSIS AND POWER CALCULA-
TION. The null hypothesis that the maximum
troponin T increase over baseline within 48 h is equal
in patients with esmolol therapy versus placebo was
tested using the Mann-Whitney U test. The treatment
effect was quantiﬁed using an estimator for the dif-
ference of the location parameters in the esmolol and
placebo groups on the basis of normal approximation,
with a corresponding continuity-corrected 95% con-
ﬁdence interval (CI). Note that the estimator for the
difference in location parameters does not estimate
the difference in medians but rather the median of
the difference between a sample from the esmolol
group and a sample from the placebo group.
For the secondary endpoints, we used unpaired
Student t tests, Mann-Whitney U tests, and Fisher
exact tests to perform pairwise treatment compari-
sons. To elaborate on the impact of medical treatment
on troponin T release, we ﬁtted a multivariable linear
regression model using log-transformed peak
troponin T level within 48 h as the dependent vari-
able and treatment, and mean heart rate during 24 h
of study intervention and log-transformed baseline
troponin T level as the independent variables. After
transformation, the troponin T values appeared nor-
mally distributed. The interaction treatment * mean
heart rate was explored. For estimation of myocardial
areas at risk during infarction the angiographic
Bypass Angioplasty Revascularization Investigation
Myocardial Jeopardy Index (BARI) and Alberta Pro-
vincial Project for Outcome Assessment in Coronary
Heart Disease scores (APPROACH) were calculated as
previously described elsewhere (17,18).
FIGURE 1 Consort Diagram
Consort diagram demonstrating enrollment, allocation, follow-up observation, and analysis.
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234All reported p values are 2-sided. A difference in
the primary endpoint was considered statistically
signiﬁcant if the corresponding test was p < 0.05. The
further analyses were regarded as explorative, and
the p values of the corresponding tests are presentedfor descriptive reasons only. Analyses were per-
formed for the intention-to-treat analysis set (pri-
mary) and the per-protocol analysis set (secondary,
yielding similar results [data not shown]). IBM SPSS
Statistics version 22 (IBM, SPSS/IBM, Chicago, Illinois)
TABLE 1 Baseline Data
Total
(N ¼ 100)
Esmolol Group
(n ¼ 50)
Placebo Group
(n ¼ 50)
p
Value
Age, yrs 59.7  11.8 57.9  11.2 61.4  12.2 0.14*
Male 77 (77) 41 (82) 36 (72) 0.34†
Body mass index, kg/m2 26.4  4.0 26.6  3.8 26.1  4.1 0.51*
Known coronary artery disease (%) 12 (12) 5 (10) 7 (14) 0.76†
Previous myocardial infarction (%) 7 (7) 3 (6) 4 (8) 1.00†
Previous coronary intervention (%) 7 (7) 2 (4) 5 (10) 0.44†
Hypertension 54 (54) 27 (54) 27 (54) 1.0†
Smoking 52 (52) 30 (60) 22 (44) 0.16†
Dyslipidemia 29 (29) 13 (26) 16 (32) 0.66†
Diabetes mellitus 12 (12) 6 (12) 6 (12) 1.0†
eGFR (ml/min) 90.7  23.6 91.5  21.0 89.8  26.0 0.71*
Infarct-related artery‡
LAD 43 (43.4) 17 (34) 26 (53.1) 0.134†
RCX 10 (10.1) 5 (10) 5 (10.2)
RCA 46 (46.5) 28 (56) 18 (36.7)
BARI index (%) 38.93  5.38 38.77  5.57 39.09  5.21 0.35*
APPROACH score (%) 41.07  4.41 41.23  4.56 40.91  4.29 0.40*
SBP at baseline, mm Hg 137.8  21.6 137.4  20.7 138.2  22.6 0.87*
Heart rate at baseline, beats/min 79.4  14.6 79.5  14.7 79.4  14.6 0.97*
Values are mean  SD or n (%). *Student t test. †Fisher exact test. ‡One patient with infarct related to LAD and
RCX excluded.
APPROACH ¼ Alberta Provincial Project for Outcome Assessment in Coronary Heart Disease; BARI ¼ Bypass
Angioplasty Revascularization Investigation Myocardial Jeopardy Index; eGFR ¼ estimated glomerular ﬁltration
rate; LAD ¼ left anterior descending; RCA ¼ right coronary artery; RCX ¼ ramus circumﬂexus; SBP ¼ systolic
blood pressure.
TABLE 2 Primary Endpoint: Troponin T Release in Study Population
Total
(N ¼ 100)
Esmolol Group
(n ¼ 50)
Placebo Group
(n ¼ 50) p Value
Baseline troponin T (ng/ml) 0.252
Median (IQR) 0.3 (0.1–1.0) 0.2 (0.1–0.7) 0.3 (0.1–1.2)
Mean  SD 0.7  1.0 0.6  0.9 0.8  1.1
Maximum troponin T (ng/ml) 0.009
Median (IQR) 2.4 (0.9–5.2) 1.3 (0.6–4.7) 3.2 (1.5–5.3)
Mean  SD 3.8  4.3 2.9  3.6 4.6  4.8
Maximum change in troponin
T from baseline to 48 h
(ng/ml)
0.010
Median (IQR) 1.7 (0.6–3.9) 1.0 (0.3–3.5) 2.5 (1.0–4.0)
Mean  SD 3.0  3.9 2.3  3.1 3.8  4.5
AUC troponin T (ng * h/ml) 0.043
Median (IQR) 70.7 (27.4–143.8) 38.4 (17.5–151.4) 88.3 (40.2–135.6)
Mean  SD 104.8  111.7 90.6  108.3 119.1  114.4
Time to peak troponin T (h) 0.018
Median (IQR) 6 (6–12) 12 (6–18) 6 (6–12)
Mean  SD 11.8  10.6 14.0  11.8 9.6  8.7
The p values are from Mann-Whitney U test.
AUC ¼ area under the curve; IQR ¼ interquartile range.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 9 , N O . 3 , 2 0 1 6 Er et al.
F E B R U A R Y 8 , 2 0 1 6 : 2 3 1 – 4 0 Sympathetic Control in STEMI
235and R version 3.1.0 (R Foundation, Vienna, Austria)
were used for statistical analyses.
On the basis of our own observation (unpublished
data), a heart rate reduction of maximum 10 beats/min
with esmolol was assumed, and a reduction in mean
troponin T max (primary variable) of about 3 z 0.5 *
5.87 mg/l was expected on the basis of the hypothesis
that heart rate reduction is responsible for prevention
of troponin T release for at least for 50%. Assuming a
coefﬁcient of variation of 1, this troponin T reduction
may be detected with 92% power, obtained by
simulation, using the Welch-modiﬁed t test with 50
patients per treatment group (at 5% two-sided signif-
icance level). In a non-simulation-based approach this
roughly corresponds to a delta/sigma of 0.67 (¼ 3/4.5),
assuming equal within-group variances. Thus, a
sample size of 50 patients per treatment group (i.e.,
100 in total) seems sufﬁcient to assess presumably
relevant effects of study treatment. This remains true
even when accounting for a maximum 5% dropout rate
(we expect virtually none due to the in-hospital
setting) and up to 5% power loss due to nonpara-
metric testing.
RESULTS
PATIENTS. A total of 101 patients were enrolled be-
tween October 2011 and February 2014 (Figure 1). One
patient (placebo group) was excluded per protocol
after randomization due to elevated serum-lactate-
dehydrogenase indicating subacute myocardial
infarction. All patients received the complete allo-
cated therapy. The basic demographic and clinical
characteristics of treatment groups were similar as
was the estimation of myocardial areas at risk re-
ﬂected by calculated BARI and APPROACH scores
(Table 1). Twenty-one (esmolol group) versus 20
(placebo group) patients were in Killip class II. The
mean age of the study population was 59.7  11.8
years, and 77% were men. A frequent comorbidity was
hypertension in 54%, and 12% had a history of coro-
nary artery disease. The time between symptom onset
and reperfusion (symptom to balloon time) was
157.0 min (IQR: 116 to 236 min) in the esmolol group
and 162.5 min (IQR: 85 to 238 min) in the placebo
group (p ¼ 0.98). The baseline heart rate was similar in
both groups, at 79.5  14.7 beats/min (esmolol group)
and 79.4  14.6 beats/min (placebo group, p ¼ 0.97).
The 24-h average heart rate was 68.4  9.0 beats/min
in the esmolol group and 73.8  12.4 in the placebo
group (p ¼ 0.014) (Online Table 1, Online Figure 1). At
admission, 11 patients were on oral beta-blocker
treatment (Online Table 2). Nineteen patients (esmo-
lol group n ¼ 9 vs. placebo group n ¼ 10) received anoral beta-blocker during the ﬁrst 24 h, and 86 patients
within 48 h (esmolol group n ¼ 45 vs. placebo group
n ¼ 41) after PCI.
PRIMARY ENDPOINT. The maximum change in
troponin T within 48 h was statistically signiﬁcantly
FIGURE 2 Study Endpoints
Time-dependent serum concentration of (A) troponin T, (B)
creatine kinase, and (C) creatine kinase subunit MB in patients.
Data are presented as back-transformed mean  95% conﬁ-
dence bounds for each time point of serum determination after
using their natural logarithms for calculations.
FIGURE 3 Association Between Heart Rate and
Troponin T Release
Scatter plot displaying correlation betweenmeanheart rate during
intervention and peak troponin T level from baseline to 48 h by
treatment. Lines show the adjusted effect of esmolol (solid line)
and placebo (dotted line) on troponin T release and result from
ﬁtted regression model substituting the mean baseline troponin
T level: Peak troponin T level¼ exp(0.285 0.417 * Treatmentþ
0.619 * log(Baseline troponin T)þ 0.019 * mean heart rate during
intervention.
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236higher in the placebo group (2.5 ng/ml, IQR: 1.0 to
4.0 ng/ml) than in the esmolol group (1.0 ng/ml, IQR:
0.3 to 3.5 ng/ml; p ¼ 0.010). The estimated difference
in location parameters was 0.89 (95% CI: 1.87 to
0.17). The baseline serum troponin T was similar in
both groups, with 0.2 ng/ml (IQR: 0.1 to 0.7 ng/ml) in
esmolol group versus 0.3 ng/ml (IQR: 0.1 to 1.2 ng/ml)in placebo group. The peak troponin T was 1.3 ng/ml
(IQR: 0.6–4.7) in the esmolol group versus 3.2 ng/ml
(IQR: 1.5–5.3) in the placebo group (p ¼ 0.009, Table 2;
Online Table 3). The peak troponin T was delayed in
time in the esmolol group (12 h, IQR: 6–18) compared
with the placebo group (6 h; IQR: 6–12; p ¼ 0.018).
The time-course of troponin T release revealed
an area under the curve (AUC) of 38.4 ng*h/ml
(IQR: 17.5–151.4) in the esmolol group and 88.3 ng*h/ml
(IQR: 40.2–135.6) in the placebo group (p ¼ 0.043;
Figure 2A) indicating a signiﬁcantly higher total
troponin T release over time in the placebo group.
The maximum troponin T release was weak, but
positively associated with the mean heart rate
(Spearman’s rank correlation coefﬁcient rho ¼ 0.300;
p ¼ 0.002). In the ﬁtted regression model without
interaction term, the effect of esmolol-treatment on
troponin T release was statistically signiﬁcant
(p ¼ 0.011) after adjustment for baseline troponin T
(p < 0.001) and mean heart rate (p ¼ 0.012). Inde-
pendent of heart rate and baseline troponin T con-
centration, the troponin T level in the esmolol group
was 34% reduced compared with the placebo group
(Figure 3). The infarct related artery (p ¼ 0.762) and
TABLE 3 CK and CK-MB Release in Study Population
Total
(N ¼ 100)
Esmolol Group
(n ¼ 50)
Placebo Group
(n ¼ 50) p Value
Baseline CK (U/l) 0.055
Median (IQR) 291.5 (145–537) 201.5 (126–471.0) 373 (179–550)
Mean  SD 509.2  548.0 471.6  554.0 546.8  545.0
Baseline CKMB (U/l) 0.072
Median (IQR) 34 (22–70.5) 29 (17–61) 41.5 (23–82)
Mean  SD 60.6  61.9 55.0  60.9 66.2  62.9
Peak CK (U/l) 0.013
Median (IQR) 1,033 (391.5–1,842) 619 (250–1,701) 1308 (610–2,324)
Mean  SD 1,540.8  1,699.1 1,311.2  1,736.8 1,770.4  1,645.7
Peak CKMB (U/l) 0.005
Median (IQR) 131 (46.5–244.5) 73.5 (30–192) 158.5 (74–281)
Mean  SD 188.5  211.3 145.4  179.7 231.7  232.6
AUC CK (U*h/l) 0.050
Median (IQR) 27,567 (12,349.5–49,411) 20,385 (8738–49191) 32,182.5 (18,366–52,572.5)
Mean  SD 40,364.2  41,167.4 37,152.1  43683.0 43,576.4  38,663.1
AUC CKMB (U*h/l) 0.015
Median (IQR) 3,258 (1,509–5,032.5) 2167.5 (1,050–4,710) 3725 (2,040–5,478)
Mean  SD 4291.9  4013.4 3674.7  3892.3 4909.1  4076.3
The p values are from the Mann-Whitney U test.
AUC = area under the curve; CK ¼ creatine kinase; CKMB ¼ creatine kinase subunit MB; IQR ¼ interquartile range.
TABLE 4 Safety Endpoints During Index Hospitalization
Event
Total
(N ¼ 100)
Esmolol Group
(n ¼ 50)
Placebo Group
(n ¼ 50) p Value
Death
No. of patients with event 1 0 1 1.0
Ventricular tachycardia
No. of events 21 4 17 —
No. of patients with event 15 4 11 0.091
Atrial ﬁbrillation
No. of events 5 1 4 —
No. of patients with event 4 1 3 0.617
Bradycardia
No. of events 2 0 2 —
No. of patients with event 1 0 1 1.0
Cardiogenic shock
No. of events 3 0 3 —
No. of patients with event 3 0 3 0.242
Reinfarction
No. of events 2 0 2 —
No. of patients with event 2 0 2 0.495
The p values are from Fisher exact test.
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237time to reperfusion (p ¼ 0.357) did not additionally
inﬂuence the troponin T release.
SECONDARY ENDPOINTS. Although the creatine ki-
nase (CK) and CK subunit MB (CK-MB) levels were
similar at baseline in both groups (Table 3), total CK
and CK-MB release was lower in the esmolol group
than in the placebo group (CK: esmolol group 619 U/l,
IQR: 250 to 1,701 U/l, vs. placebo group 1308 U/l, IQR:
610 to 2,324 U/l; p ¼ 0.013; CK-MB: esmolol group 73.5
U/l, IQR: 30 to 192 U/l, vs. placebo group 158.5 U/l,
IQR: 74 to 281 U/l; p ¼ 0.005). The time course
calculation of CK release demonstrated an AUC of
20,385 U*h/ml (IQR: 8,738 to 49,191 U*h/ml) in the
esmolol group versus 32,183 ng*h/ml (IQR: 18,366 to
52,573 ng*h/ml) in the placebo group (p ¼ 0.050;
Figure 2B). Similar relation was seen for CK-MB
release (esmolol group AUC 2,168 U*h/l, IQR: 1,050
to 4,710 U*h/l, vs. placebo group AUC: 3,725 U*h/l,
IQR: 2,040 to 5,478 U*h/l; p ¼ 0.015) (Figure 2C).
At baseline, the serum concentration of N-terminal
pro BNP (NT-proBNP) was 83.5 pg/ml (IQR: 48 to
287 pg/ml) in the esmolol group versus 133.5 pg/ml
(IQR: 61 to 341 pg/ml) in the placebo group (p ¼ 0.228),
and it increased within 48 h to 1,048 pg/ml (IQR: 623
to 2,062 pg/ml, esmolol group) and 1,497 pg/ml
(IQR: 739 to 3,318 pg/ml, placebo group; p ¼ 0.059).
The peak NT-proBNP increase from baseline was
766.5 pg/ml (IQR: 325 to 1,443 pg/ml, esmolol group)
versus 1134.5 pg/ml (IQR: 591 to 2,610 pg/ml, placebo
group; p ¼ 0.040) (Online Figure 2).CLINICAL AND SAFETY ENDPOINTS. One patient in
the placebo group died during index hospitalization
due to cardiogenic shock. A total of three patients
(esmolol group, n ¼ 0, vs. placebo group, n ¼ 3)
developed cardiogenic shock with the necessity of
intravenous catecholaminergic therapy (Table 4).
During the intravenous treatment period of 24 h, a
median number of 63 ventricular extrasystoles
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238(IQR: 20 to 283, range 0 to 999) were counted in all
patients. In the esmolol-treated patients, the ven-
tricular extrasystoles incidence (27/24 h, IQR: 16 to
123 h) was statistically signiﬁcantly lower than in the
placebo group (152/24 h, IQR: 37 to 418 h; p ¼ 0.002).
Nonsustained ventricular tachycardia occurred in
four patients in the esmolol group and 11 patients in
the placebo group (p ¼ 0.091). A higher degree
atrioventricular block (II and III) occurred in none of
the patients.
The baseline echocardiography after the study
intervention revealed a left ventricular ejection
fraction of 58.8  10.2% in the esmolol group and
55.0  11.7% in the placebo group (p ¼ 0.087). After
6 weeks, the ejection fraction was 62.5  8.8% in the
esmolol group and 58.6  9.3% in the placebo group
(p ¼ 0.035), and after 6 months it was 61.7  9.6% in
the esmolol group versus 60.1  10.1% in the pla-
cebo group (p ¼ 0.407). The median 6-week 6-min
walk distance was 550 m (IQR: 490 to 580 m,
esmolol group) versus 500 m (IQR: 415 to 550 m,
placebo group; p ¼ 0.015). After 6 months, a differ-
ence in walking distance was still present with
550 m (IQR: 475 to 580 m, esmolol group) versus
510 m (IQR: 380 to 550 m, placebo group; p ¼ 0.027).
The incidence of major cardiovascular events was
similar in both groups (Online Table 4).
DISCUSSION
In the present investigator-initiated trial, heart rate
and sympathetic control with esmolol limited the
troponin T, CK, and CK-MB release by one-third and
almost halved the release of NT-proBNP compared
with the control patients. Esmolol treatment reduced
the incidence of ventricular extrasystoles without
increasing the risk for cardiogenic shocks. Use of
continuous intravenous esmolol over a period of 24 h
was safe and well tolerated.
Although a generally elevated heart rate has
been identiﬁed as a prognostic indicator in AMI,
heart rate has not been evaluated as a potential
therapeutic target. The hypothesis of this research
was whether heart rate modulation might inﬂuence
the myocardial damage in the period of early PCI in
acute myocardial infarction. The previous VIVIFY
VIVIFY (eValuation of the IntraVenous If inhibitor
ivabradine after STsegment elevation mYocardial
infarction) study demonstrated that isolated slow-
ing of the heart rate with ivabradine was not
associated with marked positive effects on cardiac
biomarkers. This suggested that heart rate is a
surrogate for the sympathetic drive and not detri-
mental in itself (19).Early generation cardiologists of the pre-
reperfusion era were able to improve the prognosis
in AMI with suppression of sympathetic activity
simply by sedation of patients (20–22). Several trials
in the pre-reperfusion (23,24), thrombolysis (10), and
PCI era have evaluated the effects of acute beta-
blockade in AMI with controversial results. The
BEAT-AMI is the ﬁrst trial to evaluate the effects of
controlling the sympathetic drive with intravenous
beta-blockade using the heart rate as an indicator in
patients with successful PCI in STEMI.
The exact mechanisms of beneﬁcial effects of early
beta-blockers in AMI remain unclear. It has been
suggested that early intravenous administration may
quickly decrease myocardial oxygen consumption,
reduce fatal ventricular tachyarrhythmias, and
reduce infarct size by favorable inﬂuencing of the
coronary blood ﬂow (25,26). In addition, AMI results
in substantial and sustained release of catechol-
amines, which leads to a wide range of hemodynamic,
metabolic, and immune changes. Moreover, cate-
cholamines have been shown to up-regulate the
function of monocytes and potentiate the stimulating
effect of lipopolysaccharides on monocytes and
macrophages, which crucially involves the destabili-
zation of atherosclerotic plaques via the interaction of
catecholamines with beta1-receptors (27). Thus, early
inhibition of the catecholamine-mediated effects on
monocytes by beta-blockers may contribute, at least
in part, to the beneﬁcial effects of esmolol in AMI.
Likewise, the esmolol-induced decreased heart rate
improved the stroke volume and thereby the efﬁ-
ciency of myocardial work and oxygen consumption,
and reduced the catecholamine-induced toxicity in
patients with septic shock (28). There was an associ-
ated improvement in 28-day survival.
The recent elegant METOCARD-CNIC (Effect of
Metoprolol in Cardioprotection During an Acute
Myocardial Infarction) trial evaluated the effects of
early administration of metoprolol in STEMI patients
(29). Despite some differences in study design
compared to the BEAT-AMI trial, the METOCARD-
CNIC investigators demonstrated positive effects of
pre-PCI intravenous beta-blockade on myocardial
salvage in long-term clinical follow-up (30). Control-
ling the heart rate was not aim of that study, so heart
rate comparisons were not performed. In STEMI pa-
tients with early PCI, the additional development of
potentially beneﬁcial strategies is challenging (31).
Our study suggests that heart rate and sympathetic
control might be suitable modiﬁable candidates.
Differentiated calculations in the present trial
revealed that a one beat lower heart rate was associ-
ated with an average reduction in troponin T by 2%.
PERSPECTIVES
WHAT IS KNOWN? Routine intravenous administration of a
beta-blocker is not recommended during the acute phase of
myocardial infarction.
WHAT IS NEW? In Killip class I and II STEMI patients, intrave-
nous esmolol-induced control of sympathetic activity showed
beneﬁcial effects, decreasing troponin T, CK, CK-MB, and
NT-proBNP release as surrogate markers for myocardial injury.
WHAT IS NEXT? There is a need for further studies to identify
the effects of suggested esmolol-induced infarct size limitation
on clinical endpoints.
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239Considering the heart rate reduction effect, multi-
variate regression analysis revealed that esmolol
treatment itself was associated with myocardial pro-
tection, indicating that the demonstrated results are
composed of both heart rate reduction and esmolol
effects, independent of the heart rate reduction.
Further investigations are needed to identify addi-
tional pathways of esmolol effects in myocardial
protection.
CONCLUSIONS
Quantiﬁcation of cardiac damage during STEMI can
be performed by cardiac imaging techniques and
evaluation of biomarkers. The relation of troponin
release and visualization of infarct size via magnetic
resonance imaging have been extensively examined,
and a strong correlation has been demonstrated
(32–36). The BEAT-AMI trial was designed not only to
estimate the myocardial infarct size but also to assess
differences in prognostic biomarkers as surrogates for
cardiac morbidity and mortality. Biomarker evalua-
tion is a limitation of the study due to indirect esti-
mation of myocardial damage. On the other hand, all
the evaluated biomarkers—troponin (37–41), CK
(42,43), CKMB (38,44), and NT-proBNP (45–48)—have
been identiﬁed as strong prognostic indicators in
patients with AMI. In the BEAT-AMI trial, all four
evaluated biomarkers were signiﬁcantly lowered by
esmolol-induced heart rate control, indicating a pro-
tective effect of acute intravenous esmolol. Patientsin the BEAT-AMI trial were at very low risk (Killip
class I and II), and reperfusion was established within
3 h after symptom onset. The BEAT-AMI trial was
performed as a pilot trial and was not powered to
demonstrate changes in clinical endpoints. Our pre-
sent study justiﬁes a large, multicenter, prospective
evaluation of heart rate control in STEMI patients.
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